Investor Presentaiton

Our Specialty Initiatives Ramping up Specialty Pipeline In-licensed Ilumya (a monoclonal antibody targeting IL-23) from MSD for treating chronic plaque psoriasis- Biologics License Application (BLA) Filed with US FDA and EMA for European market. USFDA approval received in March 2018. Launch preparations are ongoing. • Acquired Ocular Technologies - Gives access to global rights for OTX-101 - for treating Dry Eye Disease. Announced positive results from confirmatory Phase-3 trials in Jan'17. Filed NDA with USFDA in Q3 FY18. Evaluate other markets for filing OTX-101. . Acquired branded oncology product – Odomzo – in Dec'16. Product is approved in 30 countries globally including US, Europe and Australia. Currently marketed in US and Germany. • Launched BromSite - first specialty ophthalmology product in US in Nov'16 • Acquired Dusa Pharma in US - Access to patented drug-device combination useful for treating Actinic Keratosis, a dermatology ailment • Acquired InSite Vision - Focuses on developing new specialty ophthalmic products, has three late stage programs. • In-licensed Xelpros (ophthalmology) and Elepsia (CNS) products from SPARC © Sun Pharmaceutical Industries Limited. All Rights Reserved. SUN PHARMA 8

View entire presentation